Payment overview · 2025
General Payments
$601.98
20 reported records · 10 companies
Healthcare provider profile · identity verified
Ruth A. Mcdowell, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · SOUTH BEND, IN · NPI 1619069606
Verified facts
What the public records show
CMS Open Payments records show Ruth A. Mcdowell, PA-C received $601.98 in general payments during 2025 across 20 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $169.16 | 28.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.75 | 22.9% | 7 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $121.13 | 20.1% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $54.48 | 9.1% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $34.40 | 5.7% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $21.88 | 3.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.71 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.61 | 2.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.32 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.54 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $601.98 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $169.16 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $121.13 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $113.29 | 6 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $34.40 | 2 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $30.78 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
157 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 234 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 220 | 56 |
| Lisinopril | Lisinopril | 185 | 40 |
| Atorvastatin Calcium | Atorvastatin Calcium | 179 | 46 |
| Omeprazole | Omeprazole | 172 | 47 |
| Eliquis | Apixaban | 157 | 29 |
| Furosemide | Furosemide | 148 | 36 |
| Gabapentin | Gabapentin | 132 | 33 |
| Sertraline Hcl | Sertraline Hcl | 121 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 89 | 28 |
| Losartan Potassium | Losartan Potassium | 83 | 17 |
| Metformin Hcl | Metformin Hcl | 78 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 19 |
| Trazodone Hcl | Trazodone Hcl | 67 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 15 |
| Potassium Chloride | Potassium Chloride | 62 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 12 |
| Alprazolam | Alprazolam | 49 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 42 | 15 |
| Montelukast Sodium | Montelukast Sodium | 40 | 11 |
| Simvastatin | Simvastatin | 40 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Prednisone | Prednisone | 37 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $601.98 · 20 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, ARISTADA, AUSTEDO XR, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, LYBALVI, MAVYRET, MOUNJARO, Omnipod, PREVNAR 20, VIVITROL, VRAYLAR, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error